



# SHUKRA

PHARMACEUTICALS LTD.

13<sup>th</sup> October, 2023

To  
The Manager  
BSE Limited (BSE)  
P.J. Towers, Dalal Street,  
Mumbai-400001,  
Maharashtra, India,

BSE Scrip Code: 524632

Dear Sir / Madam,

**Sub: Outcome of Meeting of Board of Directors held on October 13, 2023**

**Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This has reference to our letters dated April 19, 2023 and July 10, 2023 in relation to the **First Call and Second & Final Call** respectively, in respect of the partly paid-up Right Equity Shares of the Company.

The board of directors of the Company at its meeting held today i.e. on **Friday, October 13, 2023**, considered and approved sending of a **Final Demand cum Forfeiture Notice** for payment of First Call Money of ₹ 07.00 per partly-up Equity Share (comprising ₹ 3.50 towards face value and ₹ 3.50 towards securities premium) and Second & Final Call Money of ₹ 8.00 per partly-up Equity Share (comprising ₹ 4.00 towards face value and ₹ 4.00 towards securities premium) (*Aggregating to ₹ 15.00 per share comprising ₹ 7.50 towards face value and ₹ 7.50 towards securities premium*) to the shareholders who have failed to pay both the First and Second & final call money and payment of Second & Final Call Money of ₹ 8.00 per partly-up Equity Share (comprising ₹ 4.00 towards face value and ₹ 4.00 towards securities premium) to the shareholders who have failed to pay Second & Final Call Money only.

Failure to pay the aforesaid amount shall render the partly paid-up Equity Shares, including the amount already paid thereon, liable to be forfeited in accordance with the Companies Act, 2013, Articles of Association of the Company and the Letter of Offer dated February 01, 2023.

Further the offer period for receipt of First Call Money and/or Second & Final Call Money has been approved as follows:

Offer opening period	Monday, October 16, 2023
Offer closing period	Monday, October 30, 2023

The Board of Directors of the Company also decided to waive off the interest of 9% (Nine per cent only) p.a. as mentioned in the First Call Money Notice dated April 19, 2023 and Second & Final Call Money Notice dated July 10, 2023 for non-payment of call money by the shareholders with respect to monies payable on Calls.

**CIN : L24231GJ1993PLC019079**







# SHUKRA

PHARMACEUTICALS LTD.

In this connection, we wish to inform that the **Final Demand cum Forfeiture Notice** is being issued to the holders of such partly paid-up Equity Shares on which the First Call Money and/or Second & Final Call Money remains unpaid.

A specimen copy of the Final Demand cum Forfeiture Notice (1) for the Shareholders who have failed both the First and Second & Final Call Money, and (2) for the Shareholder who have failed to pay only Second and Final Call Money, along with the detailed instructions and Payment slip is enclosed herewith for you reference. The same is also being made available on the website of the Company at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)

This disclosure is being made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


The meeting commenced at 11.30 am and concluded at 12.15 pm.

You are requested to kindly take the same on record and disseminate.

Thanking You  
Yours Faithfully

For, Shukra Pharmaceuticals Limited

**Bhoomi Patel**  
Director  
DIN: 0836893



Encl.: a/a

**CIN : L24231GJ1993PLC019079**

**SHUKRA PHARMACEUTICALS LIMITED****Corporate Identity Number:** L24231GJ1993PLC019079**Registered Office:** 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad - 380003**Telephone:** +91-079-48000430 **Email:** [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com); **Website:** [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)**Contact Person:** Ms Arpita Kabra, Company Secretary and Compliance Officer;

**FINAL DEMAND CUM FORFEITURE NOTICE (HEREINAFTER REFERRED TO AS “FINAL DEMAND NOTICE”) TO THE HOLDERS OF PARTLY PAID-UP EQUITY SHARES OF ₹ 2.50 PER EQUITY SHARE OF SHUKRA PHARMACEUTICALS LIMITED, WHO HAVE NOT PAID THE FIRST AND SECOND & FINAL CALL MONEY PURSUANT TO THE NOTICE DATED APRIL 19, 2023 AND JULY 10, 2023 ISSUED BY THE COMPANY.**

**Date:** October 13, 2023**DP-ID / Client ID:****PAN:****Sole/ First Holder:****Address:****Joint Holder 1:****Joint Holder 2:**

Dear Shareholder/s,

**SUB: FINAL DEMAND CUM FORFEITURE NOTICE FOR PAYMENT OF FIRST AND SECOND & FINAL CALL MONEY OF ₹ 15.00 [COMPRISING OF ₹ 7.00 (INCLUDING SHARE PREMIUM OF ₹ 3.50) TOWARDS THE FIRST CALL MONEY AND ₹ 8.00 (INCLUDING SHARE PREMIUM OF ₹ 4.00) TOWARDS THE SECOND & FINAL CALL MONEY] PER PARTLYPAID-UP EQUITY SHARE ISSUED BY SHUKRA PHARMACEUTICALS LIMITED (‘COMPANY’) ON A RIGHT BASIS PURSUANT TO THE LETTER OF OFFER DATED FEBRUARY 01, 2023 (‘LETTER OF OFFER’ OR ‘LOF’)**

**REF: FIRST AND FINAL CALL MONEY NOTICE DATED APRIL 19, 2023 AND JULY 10, 2023.**

This is with reference to the First and Second & Final Call Money Notice dated April 19, 2023 and July 10, 2023. In this connection, the Board of Directors of the Company (‘**Board**’), at its meeting held on Friday, October 13, 2023, decided to give another opportunity to the shareholders holding partly paid-up equity shares of face value of ₹ 10.00/- (Rupees Ten Only) (**Rights Equity Shares**), who have not paid the First and Second & Final Call money, to pay the First and Second & Final call Money (hereinafter referred to as ‘**First Call**’ and ‘**Second & Final Call**’ for convenience). Accordingly, the Board approved the sending of Final Demand Cum Forfeiture Notice (hereinafter referred to as “**Final Demand Notice**”) for payment of ₹ 15.00 per partly paid-up equity share consisting of ₹ 7.00 (including share premium of ₹ 3.50) towards the First Call and ₹ 8.00 (including share premium of ₹ 4.00) towards the Second & Final Call, to the holders of such partly paid-up equity shares on which the First and Second & Final call money remains unpaid.

**KINDLY CONSIDER THIS AS THE FINAL DEMAND NOTICE AND YOUR LAST OPPORTUNITY TO PAY.**

As per the Company’s records, the First and Second & Final Call money for the partly paid-up equity shares of the Company held in the captioned DP ID – Client ID/Folio No. remains unpaid and hence, in accordance with the Companies Act, 2013 (‘**Act**’), Articles of Association of the Company and the Letter of Offer, the Final Demand Notice is hereby given to you to pay the First and Second & Final Call as per details given below:

No. of partly paid-up equity shares on which call amount is to be paid	Amount due and payable @ ₹ 15.00 (₹ 7.00 for First Call Money and ₹ 8.00 for Second & Final Call Money) per partly paid-up equity share (₹ in figures)

**Other Instructions**

Payment Period	From	To	Duration
	Monday, October 16, 2023	Monday, October 30, 2023	15 days
Mode of Payment	Cheque or Demand Draft payable to: <b>Shukra Pharmaceuticals Limited – A/C (For resident shareholders)</b>		

Detailed instructions for payment of the First and Second & Final Call Money are enclosed as **Annexure I**. Please read the same before proceeding for payment. You are requested to make the payment of the First and Second & Final Call Money on or before **Monday, October 30, 2023**.

The Board of Directors of the Company also decided to waive off the interest of 9% (Nine per cent only) p.a. as mentioned in the First Call Money Notice dated April 19, 2023 and Second & Final Call Money Notice dated July 10, 2023 for non-payment of call money by the shareholders with respect to monies payable on Calls.

Please note that, failure to pay the First and Second & Final Call Money, as aforesaid shall render the partly paid-up equity shares of the Company held by you, including the amount already paid thereon, liable to be forfeited in accordance with the provisions of the Companies Act, 2013, including subsequent amendments thereto, the Articles of Association of the Company and the Letter of Offer.

The final demand cum forfeiture notice is also available on the Company's website at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com).

All capitalized terms not defined herein would have the same meaning as attributed to it in the Letter of Offer.

**FOR SHUKRA PHARMACUTICALS LIMITED**

**Sd/-**

**DAKSHESH SHAH**

**MANAGING DIRECTOR**

*Encl.: As Above*

## ANNEXURE - I

### 1. MODE OF DISPATCH

In terms of the provisions of the Act, read with the relevant rules made thereunder, the Final demand Notice is being sent in electronic mode to the holders of partly paid-up equity shares who have not paid the call money or part thereof, pursuant to the First and Second & Final Call Money Notice dated April 19, 2023 and July 10, 2023 and whose e-mail address is registered with the Company or its Registrar and Transfer Agent – Purva Shareregistry (India) Private Limited (“RTA”) or the Depository Participant(s). The Final demand Notice along with the detailed instructions and payment slip are also available on the Company’s website at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com).

Physical copies of the Final Demand cum Forfeiture Notice along with the detailed instructions and payment slip are being sent to all the holders of partly paid-up equity shares who have not paid the First and Second & Final call money.

### 2. PAYMENT INSTRUCTIONS

Please note that:

- a) cash payment shall not be accepted.
- b) Payment slip along with Demand draft / Cheque should be made payable to “**Shukra Pharmaceuticals Limited - A/C**” (Account Number 029505500843) in case of resident shareholders and non-resident shareholders applying on repatriable basis or non-repatriable basis shall be sent to Purva Shareregistry (India) Private Limited at the address Office 9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus, Lower Parel East, Mumbai - 400 011, Maharashtra, India, and crossed “Account Payee Only”. Further please mention, folio no./ DP ID no./ client ID no./ no. of Rights Equity Shares at the back of the demand draft and Cheque. Cash payment shall not be accepted.
- c) Eligible Shareholders are advised to make payment in full of the First and Second & Final Call. If the amount paid is less than the First and Second & Final Call due, such amount will be adjusted @ ₹ 15.00 per partly paid-up equity share and the balance money which cannot be adjusted for a whole share will be refunded. Such Eligible Shareholder will be deemed “in arrears of payment of First and Second & Final Call” to the extent of partly paid-up equity shares on which the First and Second & Final Call remains unpaid and the consequences of failure to pay the First and Second & Final Call would apply to him.

For example - If an Eligible Shareholder holds 100 partly paid-up equity shares, the aggregate amount payable by him towards the First and Second & Final Call will be ₹ 1500. If he makes a payment of only ₹ 1050, the amount paid by him will be adjusted against 70 Partly paid-up Equity Shares and the consequence of failure to pay the First and Second & Final Call on the balance 30 partly paid-up equity shares shall apply.

- d) Please note that payments in respect of partly paid-up equity shares for a particular demat account/folio no., shall be made only once during the Payment Period (and not in multiple tranches) and the subsequent payments made, post the first payment made during the Payment Period, may be rejected at the discretion of Board of Directors or it’s duly constituted committee.
- e) Excess/duplicate/Less amount paid or amount paid by person who is not a shareholder liable for payment or short payment made by a shareholder will be refunded to the same bank account from where payment has been made.

### 3. PAYMENT MODE

- i. Shareholders are requested to send the payment slip along with demand draft / Cheque made payable to:

**Shukra Pharmaceuticals Limited – A/C**

- ii. The payment slip is enclosed herewith as **Annexure II**.
- iii. The shareholder must inter alia state the following details in the payment slip:

- a. Full Name of the Sole/First shareholder;
- b. DP ID-Client ID/Folio No.; and
- c. No. of partly paid-up equity shares.

iv. For both Resident and Non-Resident Shareholders, the payment slip along with the amount payable by demand draft / Cheque must be sent to Purva Shareregistry (India) Private Limited (Unit: **SHUKRA PHARMACUTICALS LIMITED**) at the address Office 9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus, Lower Parel East, Mumbai - 400011, Maharashtra, India, Telephone No- 022-31998810 / 4961 4132; during banking hours on or before Monday, October 30, 2023:

v. After the last date of payment, i.e., Monday, October 30, 2023, Purva Shareregistry (India) Private Limited will not accept any First and Second & final Call Money payment.

vi. The Company will not be liable for any delayed receipt and reserves the right to reject such delayed receipts.

vii. Payment slip should be complete in all respects. The payment slip found incomplete with regard to any of the particulars required to be given therein are liable to be rejected.

#### **Non-payment**

**Please note that, failure to pay the First and Second Final Call Money pursuant to the Final Demand Notice, as aforesaid, shall render the partly paid-up Right Shares, including the amount already paid thereon, liable to be forfeited in accordance with the Companies Act, the Articles of Association, and the Letter of Offer.**

#### **4. OTHER INFORMATION**

a). Please note that the trading of the ₹ 2.50 and ₹ 6.00 partly paid-up equity shares of the Company (ISIN: IN9551C01026 and IN9551C01034) has suspended on the Stock Exchanges with effect from April 13, 2023 and July 07, 2023 on account of the First and Second & Final Call respectively. Further the ISIN - IN9551C01026 and IN9551C01034 representing ₹ 2.50 and ₹ 6.00 partly paid- up equity shares has been suspended by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

b) In case of non-receipt of the Final Demand Notice, shareholders can request by e-mail or letter, for the duplicate Final Demand Notice to the Registrar, or may also download the same from the Company's website accessible at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com) or the Registrar's website accessible at [www.purvashare.com](http://www.purvashare.com). In such a case, however, the shareholder needs to fill the DP ID-Client ID, number of partly paid-up equity shares held and amount payable towards the First and Second & Final Call Money.

c) The shareholder must mention in the Application, his/her PAN number allotted under the Income Tax Act, 1961.

d) This intimation does not constitute an offer of, or a solicitation of an offer to purchase, any securities of Shukra Pharmaceuticals Limited in any jurisdiction where offers or solicitations are not permitted by law. The information is solely intended for distribution to, and use by, the Eligible Shareholders only and is not to be reproduced, transmitted or distributed to any other person.

e) All correspondence in this regard may be addressed to:



#### **PURVA SHAREREGISTRY (INDIA) PRIVATE LIMITED**

9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus,

Lower Parel East, Mumbai - 400 011, Maharashtra, India;

**Tel:** 022-3199 8810 / 4961 4132;

**E-mail:** [newissue@purvashare.com](mailto:newissue@purvashare.com)

**Website:** [www.purvashare.com](http://www.purvashare.com)

**Contact Person:** Ms. Deepali Dhuri

**SEBI Registration Number:** INR000001112



**SHUKRA PHARMACEUTICALS LIMITED****Corporate Identity Number:** L24231GJ1993PLC019079**Registered Office:** 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad - 380003**Telephone:** +91-079-48000430 **Email:** [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com); **Website:** [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)**Contact Person:** Ms Arpita Kabra, Company Secretary and Compliance Officer;**ANNEXURE - II****SHUKRA PHARMACEUTICALS LIMITED - PAYMENT SLIP FOR FIRST AND SECOND & FINAL CALL**

SHAREHOLDERS SHOULD SUBMIT THIS SLIP TO PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED, MUMBAI  
ALONGWITH DEMAND DRAFT OR CHEQUE

Name of the Sole/ First Holder:

**PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED**

Address:

9 Shiv Shakti Industrial Estate,  
J.R. Boricha Marg, Near Lodha Excelus,  
Lower Parel East, Mumbai - 400 011,  
Maharashtra, India;

DP ID – Client ID/Folio No.:

PAN:

**Sub: Notice to the holders of partly paid-up equity shares of Shukra Pharmaceuticals Limited, who have not paid the First and Second & Final Call Money pursuant to the notice dated April 19, 2023 and July 10, 2023, to make the payment of First and Second & Final Call Money within the period stated herein.**

1. I/We am/are registered member(s) of Shukra Pharmaceuticals Limited, holding partly paid-up Equity Shares
2. I/We have received the Final Demand Notice from the Company calling upon me/us to pay the First and Second & Final Call Money.
3. I/We give below my/our particulars, namely:

Name of the Sole/ First Applicant																	
Name of the Second Applicant																	
Name of the Third Applicant																	
Indian Address																	
E-mail Address																	
Contact Number																	

**TYPE OF APPLICANTS (Please tick):**Resident ☐ Non-Resident ☐*Note: Non-resident Applicants applying on non-repatriation basis should select 'Resident'.***4. REMINDER NOTICE NO.:**

DP ID and Client ID (For shares held in Dematerialised form)	No. of partly paid-up equity shares on which First and Second & Final call amounts to be paid (A)	Amount due and payable @ ₹ 15.00 (Rupees Fifteen Only) per partly paid- up Right share (₹ 7.00 for First Call Money and ₹ 8.00 for Second & Final Call Money) [(A) * ₹ 15/- (Rupees Fifteen Only)] (₹ in figures)

**5. PAYMENT DETAILS:**

DD No.	Drawn on (Bank & Branch)	Date of Payment	Demand Draft Amount (In Rupees)	Bank Serial No. (To be filled in by the Bank)

\_\_\_\_\_  
Sole/First Holder

\_\_\_\_\_  
Second Joint Holder

\_\_\_\_\_  
Third Joint Holder

Note: Signature(s) as per the specimen recorded with the Depository. In case of joint shareholders, all the joint shareholders must sign in the same sequence as per specimen recorded with the Depository.

-----Tear Here -----

**SHUKRA PHARMACEUTICALS LIMITED ACKNOWLEDGEMENT SLIP - FINAL DEMAND CUM FORFEITURE NOTICE**

Received DD No/Cheque No.\_\_\_\_ dated\_\_\_\_\_ for \_\_\_\_\_ drawn on \_\_\_\_\_ [name of bank and branch]  
for the amount aforesaid being the payment towards the First and Second & Final Call for the below mentioned partly paid-up equity shares of  
Shukra Pharmaceuticals Limited.

Date: Name of the First/ Sole Holder: DP ID-Client ID: No. of partly paid-up equity shares:	Sign and Stamp of the Collection Center   Date:
--	--



**SHUKRA PHARMACEUTICALS LIMITED****Corporate Identity Number:** L24231GJ1993PLC019079**Registered Office:** 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad - 380003**Telephone:** +91-079-48000430 **Email:** [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com); **Website:** [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)**Contact Person:** Ms Arpita Kabra, Company Secretary and Compliance Officer;

**FINAL DEMAND CUM FORFEITURE NOTICE (HEREINAFTER REFERRED TO AS “FINAL DEMAND NOTICE”) TO THE HOLDERS OF PARTLY PAID-UP EQUITY SHARES OF ₹ 6.00 PER EQUITY SHARE OF SHUKRA PHARMACEUTICALS LIMITED, WHO HAVE NOT PAID THE SECOND AND FINAL CALL MONEY PURSUANT TO THE NOTICE DATED JULY 10, 2023 ISSUED BY THE COMPANY.**

**Date:** October 13, 2023**DP-ID / Client ID:****PAN:****Sole/ First Holder:****Address:****Joint Holder 1:****Joint Holder 2:**

Dear Shareholder/s,

**SUB: FINAL DEMAND CUM FORFEITURE NOTICE FOR PAYMENT OF SECOND AND FINAL CALL MONEY OF ₹ 8.00 (COMPRISING ₹ 4.00 TOWARDS FACE VALUE AND ₹ 4.00 TOWARDS SHARE PREMIUM) PER PARTLY PAID-UP EQUITY SHARE ISSUED BY SHUKRA PHARMACEUTICALS LIMITED (‘COMPANY’) ON A RIGHT BASIS PURSUANT TO THE LETTER OF OFFER DATED FEBRUARY 01, 2023 (‘LETTER OF OFFER’ OR ‘LOF’)**

**REF: SECOND AND FINAL CALL MONEY NOTICE DATED JULY 10, 2023.**

This is with reference to the Second and Final Call Money Notice dated July 10, 2023. In this connection, the Board of Directors of the Company (‘**Board**’), at its meeting held on Friday, October 13, 2023, decided to give another opportunity to the shareholders holding partly paid-up equity shares of face value of ₹ 10.00/- (Rupees Ten Only) (**Rights Equity Shares**), who have not paid the Second and Final Call money, to pay the Second and Final call Money (hereinafter referred to as ‘**Second and Final Call**’). Accordingly, the Board approved the sending of Final Demand Cum Forfeiture Notice (hereinafter referred to as “**Final Demand Notice**”) for payment of ₹ 8.00 per partly paid-up equity share (comprising ₹ 4.00 towards face value and ₹ 4.00 towards share premium), to the holders of such partly paid-up equity shares on which the Second and Final call money remains unpaid.

**KINDLY CONSIDER THIS AS THE FINAL DEMAND NOTICE AND YOUR LAST OPPORTUNITY TO PAY.**

As per the Company’s records, the Second and Final Call money for the partly paid-up equity shares of the Company held in the captioned DP ID – Client ID/Folio No. remains unpaid and hence, in accordance with the Companies Act, 2013 (‘**Act**’), Articles of Association of the Company and the Letter of Offer, the Final Demand Notice is hereby given to you to pay the Second and Final Call Money as per details given below:

No. of partly paid-up equity shares on which call amount is to be paid	Amount due and payable @ ₹ 8.00 (₹ 4.00 towards face value and ₹ 4.00 towards share premium) per partly paid-up equity share (₹ in figures)

**Other Instructions**

Payment Period	From	To	Duration
	Monday, October 16, 2023	Monday, October 30, 2023	15 days
Mode of Payment	Cheque or Demand Draft payable to: <b>Shukra Pharmaceuticals Limited –A/C (For resident shareholders)</b>		

Detailed instructions for payment of the Second and Final Call Money are enclosed as **Annexure I**. Please read the same before proceeding for payment. You are requested to make the payment of the Second and Final Call Money on or before **Monday, October 30, 2023**.

The Board of Directors of the Company also decided to waive off the interest of 9% (Nine per cent only) p.a. as mentioned in the Second and Final Call Money dated July 10, 2023 for non-payment of call money by the shareholders with respect to money payable on the Second and Call.

Please note that, failure to pay the Second and Final Call Money, as aforesaid shall render the partly paid-up equity shares of the Company held by you, including the amount already paid thereon, liable to be forfeited in accordance with the provisions of the Companies Act, 2013, including subsequent amendments thereto, the Articles of Association of the Company and the Letter of Offer.

The final demand cum forfeiture notice is also available on the Company's website at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com).

All capitalized terms not defined herein would have the same meaning as attributed to it in the Letter of Offer.

**FOR SHUKRA PHARMACUTICALS LIMITED**

**Sd/-**

**DAKSHESH SHAH**

**MANAGING DIRECTOR**

*Encl.: As Above*

## ANNEXURE - I

### 1. MODE OF DISPATCH

In terms of the provisions of the Act, read with the relevant rules made thereunder, the Final Demand Notice is being sent in electronic mode to the holders of partly paid-up equity shares who have not paid the call money or part thereof, pursuant to the Second and Final Call Money Notice dated July 10, 2023 and whose e-mail address is registered with the Company or its Registrar and Transfer Agent – Purva Shareregistry (India) Private Limited (“RTA”) or the Depository Participant(s). The Final Demand Notice along with the detailed instructions and payment slip are also available on the Company’s website at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com).

Physical copies of the Final Demand cum Forfeiture Notice along with the detailed instructions and payment slip are being sent to all the holders of partly paid-up equity shares who have not paid the Second and Final call money.

### 2. PAYMENT INSTRUCTIONS

Please note that:

- a) cash payment shall not be accepted.
- b) Payment slip along with Demand draft / Cheque should be made payable to “**Shukra Pharmaceuticals Limited - A/C**” (Account Number 029505500843) in case of resident shareholders and non-resident shareholders applying on repatriable basis or non-repatriable basis shall be sent to Purva Shareregistry (India) Private Limited at the address Office 9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus, Lower Parel East, Mumbai - 400 011, Maharashtra, India, and crossed “Account Payee Only”. Further please mention, folio no./ DP ID no./ client ID no./ no. of Rights Equity Shares at the back of the demand draft and Cheque. Cash payment shall not be accepted.
- c) Eligible Shareholders are advised to make payment in full of the Second and Final Call. If the amount paid is less than the Second and Final Call due, such amount will be adjusted @ ₹ 8.00 per partly paid-up equity share and the balance money which cannot be adjusted for a whole share will be refunded. Such Eligible Shareholder will be deemed “in arrears of payment of Second and Final Call” to the extent of partly paid-up equity shares on which the Second and Final Call remains unpaid and the consequences of failure to pay the Second and Final Call would apply to him.

For example - If an Eligible Shareholder holds 100 partly paid-up equity shares, the aggregate amount payable by him towards the Second and Final Call will be ₹ 800. If he makes a payment of only ₹ 560, the amount paid by him will be adjusted against 70 Partly paid-up Equity Shares and the consequence of failure to pay the Second and Final Call on the balance 30 partly paid-up equity shares shall apply.

- d) Please note that payments in respect of partly paid-up equity shares for a particular demat account/folio no., shall be made only once during the Payment Period (and not in multiple tranches) and the subsequent payments made, post the first payment made during the Payment Period, may be rejected at the discretion of Board of Directors or it’s duly constituted committee.
- e) Excess/duplicate/Less amount paid or amount paid by person who is not a shareholder liable for payment or short payment made by a shareholder will be refunded to the same bank account from where payment has been made.

### 3. PAYMENT MODE

- i. Shareholders are requested to send the payment slip along with demand draft / Cheque made payable to:

**Shukra Pharmaceuticals Limited – A/C**

- ii. The payment slip is enclosed herewith as **Annexure II**.

- iii. The shareholder must inter alia state the following details in the payment slip:

- a. Full Name of the Sole/First shareholder;
- b. DP ID-Client ID/Folio No.; and
- c. No. of partly paid-up equity shares.

- iv. For both Resident and Non-Resident Shareholders, the payment slip along with the amount payable by demand draft/ Cheque must be sent to Purva Shareregistry (India) Private Limited (Unit: **SHUKRA PHARMACUTICALS LIMITED**) at the address Office 9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus, Lower Parel East, Mumbai - 400011, Maharashtra, India, Telephone No- 022-31998810 / 49614132; during banking hours on or before Monday, October 30, 2023:

- v. After the last date of payment, i.e., Monday, October 30, 2023, Purva Shareregistry (India) Private Limited will not accept any Second and Final Call Money payment.

vi. The Company will not be liable for any delayed receipt and reserves the right to reject such delayed receipts.

vii. Payment slip should be complete in all respects. The payment slip found incomplete with regard to any of the particulars required to be given therein are liable to be rejected.

#### **Non-payment**

**Please note that, failure to pay the Second and Final Call Money pursuant to the Final Demand Notice, as aforesaid, shall render the partly paid-up Right Shares, including the amount already paid thereon, liable to be forfeited in accordance with the Companies Act, the Articles of Association, and the Letter of Offer.**

#### **4. OTHER INFORMATION**

a.) Please note that the trading of the ₹ 6.00 partly paid-up equity shares of the Company (ISIN: IN9551C01034) has suspended on the Stock Exchanges with effect from July 07, 2023 on account of the Second and Final Call. Further the ISIN - IN9551C01034 representing ₹ 6.00 partly paid- up equity shares has been suspended by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

b) In case of non-receipt of the Final Demand Notice, shareholders can request by e-mail or letter, for the duplicate Final Demand Notice to the Registrar, or may also download the same from the Company's website accessible at [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com) or the Registrar's website accessible at [www.purvashare.com](http://www.purvashare.com). In such a case, however, the shareholder needs to fill the DP ID-Client ID, number of partly paid-up equity shares held and amount payable towards the Second and Final Call Money.

c) The shareholder must mention in the Application, his/her PAN number allotted under the Income Tax Act, 1961.

d) This intimation does not constitute an offer of, or a solicitation of an offer to purchase, any securities of Shukra Pharmaceuticals Limited in any jurisdiction where offers or solicitations are not permitted by law. The information is solely intended for distribution to, and use by, the Eligible Shareholders only and is not to be reproduced, transmitted or distributed to any other person.

e) All correspondence in this regard may be addressed to:



#### **PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED**

9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus,

Lower Parel East, Mumbai - 400 011, Maharashtra, India;

**Tel:** 022-31998810 / 49614132;

**E-mail:** [newissue@purvashare.com](mailto:newissue@purvashare.com)

**Website:** [www.purvashare.com](http://www.purvashare.com)

**Contact Person:** Ms. Deepali Dhuri

**SEBI Registration Number:** INR000001112



**SHUKRA PHARMACEUTICALS LIMITED****Corporate Identity Number:** L24231GJ1993PLC019079**Registered Office:** 3rd Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad - 380003**Telephone:** +91-079-48000430 **Email:** [info@shukrapharmaceuticals.com](mailto:info@shukrapharmaceuticals.com); **Website:** [www.shukrapharmaceuticals.com](http://www.shukrapharmaceuticals.com)**Contact Person:** Ms Arpita Kabra, Company Secretary and Compliance Officer;**ANNEXURE - II****SHUKRA PHARMACEUTICALS LIMITED - PAYMENT SLIP FOR SECOND AND FINAL CALL**

SHAREHOLDERS SHOULD SUBMIT THIS SLIP TO PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED, MUMBAI  
ALONGWITH DEMAND DRAFT OR CHEQUE

Name of the Sole/ First Holder:	<b>PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED</b>
Address:	9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus, Lower Parel East, Mumbai - 400 011, Maharashtra, India;
DP ID – Client ID/Folio No.:	
PAN:	

**Sub: Notice to the holders of Partly Paid-up Equity Shares of Shukra Pharmaceuticals Limited, who have not paid the Second and Final Call Money pursuant to the Notice dated July 10, 2023, to make the payment of Second and Final Call Money within the period stated herein.**

1. I/We am/are registered member(s) of Shukra Pharmaceuticals Limited, holding partly paid-up Equity Shares
2. I/We have received the Final Demand Notice from the Company calling upon me/us to pay the Second and Final Call Money.
3. I/We give below my/our particulars, namely:

Name of the Sole/ First Applicant															
Name of the Second Applicant															
Name of the Third Applicant															
Indian Address															
E-mail Address															
Contact Number															

**TYPE OF APPLICANTS (Please tick):**Resident ☐ Non-Resident ☐*Note: Non-resident Applicants applying on non-repatriation basis should select 'Resident'.***4. REMINDER NOTICE NO.:**

DP ID and Client ID (For shares held in Dematerialised form)	No. of partly paid-up equity shares on which Second and Final call amount is to be paid (A)	Amount due and payable @ ₹ 8.00 (Rupees Eight Only) per partly paid-up Right share (comprising ₹ 4.00 towards face value and ₹ 4.00 towards share premium) [(A) * ₹ 8.00 (Rupees Eight Only)] (₹ in figures)

**5. PAYMENT DETAILS:**

DD No.	Drawn on (Bank & Branch)	Date of Payment	Demand Draft Amount (In Rupees)	Bank Serial No. (To be filled in by the Bank)

\_\_\_\_\_  
Sole/First Holder

\_\_\_\_\_  
Second Joint Holder

\_\_\_\_\_  
Third Joint Holder

Note: Signature(s) as per the specimen recorded with the Depository. In case of joint shareholders, all the joint shareholders must sign in the same sequence as per specimen recorded with the Depository.

-----Tear Here -----

**SHUKRA PHARMACEUTICALS LIMITED ACKNOWLEDGEMENT SLIP - FINAL DEMAND CUM FORFEITURE NOTICE**

Received DD No/Cheque No. \_\_\_\_ dated \_\_\_\_\_ for \_\_\_\_\_ drawn on \_\_\_\_\_ [name of bank and branch] for the amount aforesaid being the payment towards the Second and Final Call for the below mentioned partly paid-up equity shares of Shukra Pharmaceuticals Limited.

Date: Name of the First/ Sole Holder: DP ID-Client ID: No. of partly paid-up equity shares:	Sign and Stamp of the Collection Center   Date:
--	--